Evidence map›Paper›PMID 30395968›Full record

ReviewMethods (San Diego, Calif.)2019

Unraveling 3'-end RNA uridylation at nucleotide resolution.

Mehdi Pirouz, Aref G Ebrahimi, Richard I Gregory

Abstract readReview
In one paragraph

Review in Methods (San Diego, Calif.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. microRNA strand selection: Unwinding the rules.Wiley interdisciplinary reviews. RNA · 2021
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mehdi PirouzStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Aref G EbrahimiSection on Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02115, USA.
Richard I GregoryStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Harvard Initiative for RNA Medicine, Boston, MA 02115, USA. Electronic address: rgregory@enders.tch.harvard.edu.
Harvard University · US

Funding

Regulation of microRNA Biogenesis in Stem CellsR01GM086386 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI GREGORY, RICHARD I. · 2009 to 2018
$3.1M
Regulation of the LIN28/let-7 pathway in cancerR01CA211328 · NCI · BOSTON CHILDREN'S HOSPITAL · PI GREGORY, RICHARD I. · 2017 to 2019
$1.2M
NCI NIH HHS R01 CA211328NIGMS NIH HHS R01 GM086386
6 · The paper itself

Abstract

Post-transcriptional modification of RNA, the so-called 'Epitranscriptome', can regulate RNA structure, stability, localization, and function. Numerous modifications have been identified in virtually all classes of RNAs, including messenger RNAs (mRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), microRNAs (miRNAs), and other noncoding RNAs (ncRNAs). These modifications may occur internally (by base or sugar modifications) and include RNA methylation at different nucleotide positions, or by the addition of various nucleotides at the 3'-end of certain transcripts by a family of terminal nucleotidylyl transferases. Developing methods to specifically and accurately detect and map these modifications is essential for understanding the molecular function(s) of individual RNA modifications and also for identifying and characterizing the proteins that may read, write, or erase them. Here, we focus on the characterization of RNA species targeted by 3' terminal uridylyl transferases (TUTases) (TUT4/7, also known as Zcchc11/6) and a 3'-5' exoribonuclease, Dis3l2, in the recently identified Dis3l2-mediated decay (DMD) pathway - a dedicated quality control pathway for a subset of ncRNAs. We describe the detailed methods used to precisely identify 3'-end modifications at nucleotide level resolution with a particular focus on the U1 and U2 small nuclear RNA (snRNA) components of the Spliceosome. These tools can be applied to investigate any RNA of interest and should facilitate studies aimed at elucidating the functional relevance of 3'-end modifications.

Indexed as

RNA Processing, Post-Transcriptional3' Flanking RegionAnimalsComputational BiologyCRISPR-Associated Protein 9CRISPR-Cas SystemsDNA-Binding ProteinsExoribonucleasesGene EditingMiceMouse Embryonic Stem CellsNucleotidyltransferasesRNA, Guide, CRISPR-Cas SystemsRNA, MessengerRNA, Small NuclearRNA StabilityCRISPR-Associated Protein 9Dis3l2 protein, mouseDNA-Binding ProteinsExoribonucleasesNucleotidyltransferasesRNA, Guide, CRISPR-Cas SystemsRNA, MessengerRNA, Small Nuclearterminal uridylyl transferase 7, mouseU1 small nuclear RNAU2 small nuclear RNAUridineZCCHC11 protein, mouse3′-end UridylationDIS3L2DIS3L2-mediated decay (DMD)snRNATUTaseU1U2

Identifiers

PMID30395968
PMCPMC6387850
OpenAlexW2899239458

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.